(Q33386019)

English

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Donald A Richards

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Paul R Kuefler

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carlos Becerra

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lalan S Wilfong

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert H Gersh

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kristi A Boehm

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Feng Zhan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lina Asmar

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott P Myrand

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rebecca R Hozak

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Luping Zhao

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John F Gill

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brian P Mullaney

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Coleman K Obasaju

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Steven J Nicol

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

28 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

144-153

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-009-9307-8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33386019&oldid=2195309763"